5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Fredun Pharmaceuticals Ltd.

•
fredungroup.comBSE: -NSE: FREDUN
Market Cap₹ 2,438 Cr.
Current Price
High / Low₹ 1,590 / 1,400
Stock P/E54.9
Book Value₹ 178
Price to Book3.46
Dividend Yield0.02 %
ROCE21.5 %
ROE16.3 %
Face Value₹ 10

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company has delivered good profit growth of 75.1% CAGR over last 5 years
  • Company has consistently been profitable over the last 5 years
  • Latest quarter profit grew 94.6% YoY, showing strong momentum
  • Company has delivered good sales growth of 36.5% CAGR over last 5 years
  • Operating margins have improved to 14.3% from 10.1%

CONS

  • Promoter holding has decreased over last 2 years: -4.6pp
  • Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT -0.07x)
  • Operating cash flow has been negative in recent years
  • Free cash flow has been persistently negative
  • Working capital days have increased from 76 to 116 days
  • Valuation is stretched - P/E of 54.9 is well above its own 5-year median (27.6)

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1899.0037.67455633.710.842901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9100.0082.59241576.410.33902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4850.0084.58184478.410.78566.003.284921.0057.3219.2733.81
4.CIPLA1385.0033.19111888.390.94785.55-39.187119.284.1316.0016.73
5.ZYDUSLIFE1121.0024.78111820.180.09990.20-34.908017.0023.9721.3924.54
6.LAURUSLABS1840.0090.9399417.450.11362.07123.942026.3129.1018.2031.50
7.LUPIN2111.0017.4696528.820.851416.9816.018276.8934.2828.8629.59
8.DRREDDY1154.0029.8996322.060.69435.60-69.108099.80-5.2113.7510.63
9.MANKIND2328.5547.0996179.610.04574.0929.124030.5912.8913.2426.30
10.AUROPHARMA1653.3025.6295127.230.241032.0325.229150.3517.4412.7620.54
11.GLENMARK2427.0038.1068495.930.10482.83927.884018.4831.3520.3520.03
12.FREDUN1474.1055.632437.880.02131.3294.092282.4890.4421.3414.34
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
6208208701,1807881,0741,0271,6741,1991,4531,6092,1312,282
5807628121,1227339989561,5941,1081,3231,4692,0152,077
Operating Profit415858585576718090130140115206
OPM %6.58%7.04%6.62%4.95%7.00%7.06%6.95%4.80%7.54%8.95%8.70%5.41%9.02%
0000000000000
Interest2629384439535081657710614586
Depreciation991010101111121416183136
Profit before Tax415858585576718090130140115206
Tax %41.13%31.76%26.75%13.29%25.17%43.60%25.26%12.06%25.17%25.17%25.17%4.06%36.04%
Net Profit24394251414353716897105111132
5.248.408.9910.778.799.0511.2914.9814.3320.6119.5320.2223.89

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
5760971131342242753484546357,475
5354871041252112473104015446,884
Operating Profit3610891428385391591
OPM %5.86%9.59%10.34%7.39%6.98%6.20%10.11%10.91%11.60%14.35%7.91%
20110221240
Interest2234459142239414
Depreciation1112223448101
Profit before Tax23623918212848591
Tax %35.87%33.72%27.62%23.76%37.17%26.33%38.28%27.17%26.40%30.21%24.84%
Net Profit12422611162133444
EPS5.364.1611.184.775.0514.2923.8433.2544.0760.68—
Dividend Payout %11.20%14.42%5.81%13.84%13.86%4.90%2.94%2.11%1.59%1.15%—

COMPOUNDED SALES GROWTH

10 Years:
31%
5 Years:
37%
3 Years:
32%

COMPOUNDED PROFIT GROWTH

10 Years:
41%
5 Years:
75%
3 Years:
45%

STOCK PRICE CAGR

10 Years:
—
5 Years:
—
3 Years:
—
1 Year:
—

RETURN ON EQUITY

10 Years:
14%
5 Years:
15%
3 Years:
16%
Last Year:
16%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2026

Jul 16

2:1

Final Dividend & Bonus issue & Audited Results

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
2344445555
2193537396384115137259
15101935405383100159202
Trade Payables233934466049596314587
1481319191827254187
Total Liabilities5679105141162187257308487642
211631313032394753118
Capital Work in Progress01100000000
0000000122
71841506846150175240270
00000006517793
Cash & Bank11131231065
283231576310664191594
Total Assets5679105141162187257308487642

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
4171-101-2-14-0-2116
Cash from Investing-7-8-5-1-1-4-9-8-6-74
Cash from Financing3-8414-1725626122
-1102-211-2-165

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
PER SHARE
EPS (₹)5.364.1611.184.775.0514.2923.8433.2544.0760.68
Book Value (₹)20.1464.7197.73103.57107.96153.07194.27255.15299.47483.87
Dividend per Share (₹)0.600.600.650.660.700.700.700.700.700.70
Cash EPS (₹)3.632.954.843.163.366.3910.0113.7717.8325.05
PROFITABILITY
Operating Margin %5.86%9.59%10.34%7.39%6.98%6.20%10.11%10.91%11.60%14.35%
Net Margin %2.52%2.94%4.60%1.69%1.50%2.82%3.93%4.49%4.58%5.23%
ROE %33.88%13.02%14.59%4.74%4.77%11.42%13.86%15.03%15.93%16.35%
ROCE %18.16%15.90%20.56%10.36%9.53%13.15%17.64%17.13%18.94%21.50%
2.88%2.59%4.84%1.54%1.33%3.63%4.86%5.53%5.24%5.88%
EFFICIENCY
Debtor Days102109629210910783529777
Inventory Days557811114816193131170167146
Payable Days290285221178190112948511593
-133-98-48618088119137149131
FINANCIAL HEALTH
Debt to Equity (x)2.53x0.45x0.49x0.84x0.92x0.78x0.98x0.88x1.18x0.84x
Interest Coverage (x)2.19x2.36x2.97x1.56x1.73x2.80x2.89x2.57x2.26x2.21x
0.87x0.97x1.36x1.27x1.50x2.07x1.55x1.54x1.29x1.68x
GROWTH
Revenue Growth %33.97%5.03%62.92%16.24%18.73%67.64%22.37%26.75%30.35%40.03%
Operating Profit Growth %9.97%12.17%80.70%-16.64%21.42%44.65%90.46%31.41%41.64%72.09%
Net Profit Growth %33.47%22.67%154.72%-57.36%5.93%214.45%70.58%44.57%33.18%59.59%
20.13%-22.38%168.74%-57.36%5.93%183.03%66.83%39.44%32.55%37.69%
VALUATION
P/E (x)11.38x34.30x37.85x24.45x91.79x64.04x32.60x21.57x15.17x27.55x
P/B (x)3.03x2.21x4.33x1.13x4.29x5.98x4.00x2.81x2.23x3.46x
Dividend Yield %0.98%0.42%0.15%0.57%0.15%0.08%0.09%0.10%0.10%0.04%
6.59x9.76x17.58x8.85x20.80x29.37x14.71x11.34x8.74x11.31x

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
49.1748.9348.9348.9348.9348.9343.0644.1744.57
0.000.000.000.000.000.010.461.061.06
1.601.591.591.591.591.613.482.832.94
Government0.000.000.000.000.000.000.000.000.00
49.2449.4849.4849.4849.4849.4553.0051.9451.43

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

No announcements filed.

News

Recent coverage and analyst commentary for FREDUN

Loading news…

🤖

AI Stock Analyst

Fredun Pharmaceuticals Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme


5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login